Evaxion Biotech announced that it has appointed Glenn S. Vraniak as Chief Financial Officer, effective October 31, 2019. Evaxion further strengthened the senior executive team with the addition of Jürgen Langhärig as Head of Business Development, and Marianne Søgaard as Senior Vice-President, Corporate Affairs and General Counsel. Langhärig joins Evaxion from Serodus.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.67 USD | +1.96% | -9.16% | -46.48% |
May. 29 | European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading | MT |
May. 28 | Earnings Flash (EVAX) EVAXION BIOTECH Reports Q1 Revenue $51,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.48% | 19.86M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- EVAX Stock
- News Evaxion Biotech A/S
- Evaxion Biotech Announces Executive Changes